Fibrinolytic properties of staphylokinase mutants obtained by 'clustered charge-to-alanine' mutagenesis

Fibrinolysis

Volumn 10, Issue 3, 1996, Pages 177-182

  Lijnen, H R ^a   Silence, K ^a   Hartmann, M ^b   Guhrs K H ^b   Gase, A ^b   Schlott, B ^b   Collen, D ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALPHA 2 ANTIPLASMIN; BACTERIAL PROTEIN; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENT; IODINE 125; MUTANT PROTEIN; PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEIN; STAPHYLOKINASE;

ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; FIBRINOLYTIC THERAPY; HAMSTER; HUMAN; HUMAN CELL; LUNG EMBOLISM; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 0029682561     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(96)80029-4     Document Type: Article

References (29)

1. Lack C H. Staphylokinase: an activator of plasma protease. Nature 1948; 161: 559-600.
2. Lewis J H, Ferguson J H. A proteolytic enzyme system of the blood. III. Activation of dog serum profibrinolysin by staphylokinase. Am J Physiol 1951; 166: 594-602.
3. Kowalska-Loth B, Zakrzewski K. The activation by staphylokinase of human plasminogen. Acta Biochim Pol 1975; 22: 327-39.
4. Collen D, Schlott B, Engelborghs Y, Van Hoef B, Hartmann M, Lijnen H R, Behnke D. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J Biol Chem 1993; 268: 8284-89.
5. Matsuo O, Okada K, Fukao H, et al. Thrombolytic properties of staphylokinase. Blood 1990; 76: 925-9.
6. Lijnen H R, Van Hoef B, De Cock F, et al. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991; 266: 11826-32.
7. Lijnen H R, Stassen J M, Vanlinthout I, et al. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Thromb Haemostas 1991; 66: 468-73.
8. Collen D, De Cock F, Vanlinthout I, Declerck P J, Lijnen H R, Stassen J M. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 1992; 6: 232-42.
9. Collen D, De Cock F, Stassen J M. Comparative immunogenicity and thrombolytic properties towards arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 1993; 87: 996-1006.
10. Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87: 1850-53.
11. Schlott B, Hartmann M, Gürhs K H, et al. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Biotechnology 1994; 12: 185-89.
12. Vanderschueren S, Barrios L, Kerdsinchai P, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044-49.
13. Vanderschueren S, Stockx L, Wilms G, et al. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation 1995; 92: 2050-57.
14. 2-plasmin inhibitor. Biochem Biophys Res Commun 1989; 162: 830-37.
15. 2-antiplasmin. J Biol Chem 1993; 268: 9811-16.
16. 2-antiplasmin and fibrin. Biochim Biophys Acta 1992; 1118: 144-48.
17. 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma. Blood 1993; 82: 1175-83.
18. Damaschun G, Damaschun H, Gast K, et al. Physical and conformational properties of staphylokinase in solution. Biochim Biophys Acta 1993; 1161: 244-48.
19. Silence K, Hartmann M, Gührs K-H, et al. Structure-function relationships in staphylokinase as revealed by 'clustered charge-to-alanine' mutagenesis. J Biol Chem 1995; 270: 27192-98.
20. Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
21. Collen D, Silence K, Demarsin E, De Mol M, Lijnen H R. Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis 1992; 6: 203-13.
22. Declerck P J, Vanderschueren S, Billiet J, Moreau H, Collen D. Prevalence and induction of circulating antibodies against recombinant staphylokinase. Thromb Haemostas 1994; 71: 129-33.
23. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemat 1957; 17: 237-46.
24. Edy J, Collen D, Verstraete M. Quantification of the plasma protease inhibitor antiplasmin with the chromogenic substrate S-2251. In: Davidson J F, Rowan R M, Samama M M, Desnoyers P C, eds. Progress in chemical fibrinolysis and thrombolysis, Vol 3. New York: Raven Press, 1978: 315-22.
25. Lijnen H R, Van Hoef B, Vandenbossche L, Collen D. Biochemical properties of natural and recombinant staphylokinase. Fibrinolysis 1992; 6: 214-25.
26. Stassen J M, Vanlinthout I, Lijnen H R, Collen D. A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents. Fibrinolysis 1990; 4: 15-21.
27. Bennett W F, Paoni N F, Keyt B A, et al. High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem 1991; 266: 5191-201.
28. r single-chain urokinase-type plasminogen activator. Thromb Haemostas 1994; 71: 134-40.
29. Collen D, Mao J-I, Stassen J M, et al. Thrombolytic properties of Lys158 mutants of recombinant single chain urokinase-type plasminogen activator in rabbits with jugular vein thrombosis. J Vase Med Biol 1989; 1: 46-49.